Bontoc NR Hydrogen Malate Awarded U.S. Patent
On August 5, Bontac NR Hydrogen Malate product successfully obtained a patent certificate issued by the United States Patent and Trademark Office (USPTO) (Publication No.: US12378279B2), marking another authoritative recognition of Bontac innovation strength in the international biotechnology field. This is also the latest overseas patent obtained after the company’s cumulative filing of more than 190 patent applications worldwide, showcasing its strong R&D capabilities and technological barriers.
PART 01
NRHM (NR Hydrogen Malate): A New Breakthrough in the Anti-Aging Field
NRHM (Nicotinamide Riboside Hydrogen Malate), the malate form of NR, represents Bontac latest research achievement in the NAD+ precursor field. As a novel NAD+ booster, it offers the following significant advantages over traditional NR (Nicotinamide Riboside):
- Higher stability: Significantly less sensitive to light, air, and humidity, maintaining good chemical stability even when exposed to adverse environmental factors.
- Higher bioavailability: The malate form significantly improves the absorption rate of active ingredients in the human body.
- More stable chemical properties: Solves the technical problem of the instability and easy decomposition of traditional NR.
- Better taste: Reduces the bitter taste of traditional NR, improving user compliance.
- Higher heat stability: Maintains good stability even at elevated temperatures, optimizing production processes, increasing efficiency, and offering better druggability and broader application scenarios.
PART 02
Opportunities in the Anti-Aging Market
With the intensifying trend of global aging, the NAD+ supplement market is experiencing explosive growth. According to Grand View RLesearch, the global NAD+ supplement market reached USD 580 million in 2022 and is expected to exceed USD 2 billion by 2030. At the same time, this technology can be extended to functional foods, medical foods, and other sectors, offering broad market prospects.
In addition, Bontac is the first company in the world to be granted an invention patent for the crystalline form of Nicotinamide Riboside Hydrogen Malate (NRHM), having obtained the exclusive patent authorized by the China National Intellectual Property Administration: [A Crystalline Form of Nicotinamide Riboside Hydrogen Malate and its Preparation Method and Application] (Chinese Invention Patent: 202410881394.X). The acquisition of both domestic and international patents marks another milestone in the development of coenzyme raw materials and reflects the company’s focus and commitment to innovative R&D.
PART 03
Continuous Innovation Leading Industry Development
The acquisition of the U.S. patent not only reinforces Bontac leadership in the global NAD+ field but also sets a successful example for Chinese biotech companies expanding internationally. Guided by the “Healthy China” and “Technology Powerhouse” strategies, more Chinese enterprises are expected to shine on the global stage. In the future, Bontac Biotech will continue to uphold its spirit of innovation, promoting the development of the synthetic biology sector and contributing to the cause of human health.
PART 01
NRHM (NR Hydrogen Malate): A New Breakthrough in the Anti-Aging Field
NRHM (Nicotinamide Riboside Hydrogen Malate), the malate form of NR, represents Bontac latest research achievement in the NAD+ precursor field. As a novel NAD+ booster, it offers the following significant advantages over traditional NR (Nicotinamide Riboside):
- Higher stability: Significantly less sensitive to light, air, and humidity, maintaining good chemical stability even when exposed to adverse environmental factors.
- Higher bioavailability: The malate form significantly improves the absorption rate of active ingredients in the human body.
- More stable chemical properties: Solves the technical problem of the instability and easy decomposition of traditional NR.
- Better taste: Reduces the bitter taste of traditional NR, improving user compliance.
- Higher heat stability: Maintains good stability even at elevated temperatures, optimizing production processes, increasing efficiency, and offering better druggability and broader application scenarios.
PART 02
Opportunities in the Anti-Aging Market
With the intensifying trend of global aging, the NAD+ supplement market is experiencing explosive growth. According to Grand View RLesearch, the global NAD+ supplement market reached USD 580 million in 2022 and is expected to exceed USD 2 billion by 2030. At the same time, this technology can be extended to functional foods, medical foods, and other sectors, offering broad market prospects.
In addition, Bontac is the first company in the world to be granted an invention patent for the crystalline form of Nicotinamide Riboside Hydrogen Malate (NRHM), having obtained the exclusive patent authorized by the China National Intellectual Property Administration: [A Crystalline Form of Nicotinamide Riboside Hydrogen Malate and its Preparation Method and Application] (Chinese Invention Patent: 202410881394.X). The acquisition of both domestic and international patents marks another milestone in the development of coenzyme raw materials and reflects the company’s focus and commitment to innovative R&D.
PART 03
Continuous Innovation Leading Industry Development
The acquisition of the U.S. patent not only reinforces Bontac leadership in the global NAD+ field but also sets a successful example for Chinese biotech companies expanding internationally. Guided by the “Healthy China” and “Technology Powerhouse” strategies, more Chinese enterprises are expected to shine on the global stage. In the future, Bontac Biotech will continue to uphold its spirit of innovation, promoting the development of the synthetic biology sector and contributing to the cause of human health.
.jpg?imageView2/1/w/360/h/200)
